Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1976 1
1978 2
1981 1
1982 2
1983 1
1986 2
1987 5
1988 1
1989 4
1990 5
1991 1
1992 4
1993 1
1994 2
1995 1
1996 1
1999 1
2001 1
2003 1
2005 1
2006 2
2015 1
2016 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

42 results

Results by year

Filters applied: Meta-Analysis, Randomized Controlled Trial. Clear all
Page 1
Inosine pranobex--is a single positive trial enough?
Kweder SL, Schnur RA, Cooper EC. Kweder SL, et al. N Engl J Med. 1990 Jun 21;322(25):1807-9. doi: 10.1056/NEJM199006213222509. N Engl J Med. 1990. PMID: 1693175 Clinical Trial. No abstract available.
Inosine pranobex is safe and effective for the treatment of subjects with confirmed acute respiratory viral infections: analysis and subgroup analysis from a Phase 4, randomised, placebo-controlled, double-blind study.
Beran J, Šalapová E, Špajdel M; Isoprinosine Study (EWO ISO-2014/1) Team. Beran J, et al. BMC Infect Dis. 2016 Nov 7;16(1):648. doi: 10.1186/s12879-016-1965-5. BMC Infect Dis. 2016. PMID: 27821093 Free PMC article. Clinical Trial.
BACKGROUND: Inosine pranobex (Isoprinosine) is an immunomodulatory drug approved in several countries for the treatment of viral infections. ...Inosine pranobex was generally well tolerated, and no deaths were reported. ...
BACKGROUND: Inosine pranobex (Isoprinosine) is an immunomodulatory drug approved in several countries for the treatment of vir …
Multicenter randomized study of inosine pranobex versus acyclovir in the treatment of recurrent herpes labialis and recurrent herpes genitalis in Chinese patients.
You Y, Wang L, Li Y, Wang Q, Cao S, Tu Y, Li S, Bai L, Lu J, Wei Z, Chen W, Hao F. You Y, et al. J Dermatol. 2015 Jun;42(6):596-601. doi: 10.1111/1346-8138.12845. Epub 2015 Mar 26. J Dermatol. 2015. PMID: 25819042 Clinical Trial.
Patients were assigned to treatment in one of two groups: (i) inosine pranobex group (active inosine pranobex, 1 g four times daily, and acyclovir placebo); or (ii) acyclovir group (active acyclovir, 200 mg five times daily, and inosine prano
Patients were assigned to treatment in one of two groups: (i) inosine pranobex group (active inosine pranobex, 1 …
The efficacy of inosine pranobex in preventing the acquired immunodeficiency syndrome in patients with human immunodeficiency virus infection. The Scandinavian Isoprinosine Study Group.
Pedersen C, Sandström E, Petersen CS, Norkrans G, Gerstoft J, Karlsson A, Christensen KC, Håkansson C, Pehrson PO, Nielsen JO, et al. Pedersen C, et al. N Engl J Med. 1990 Jun 21;322(25):1757-63. doi: 10.1056/NEJM199006213222501. N Engl J Med. 1990. PMID: 1693173 Free article. Clinical Trial.
We conclude that treatment with inosine pranobex delays progression to AIDS in patients with HIV infection. The duration of this beneficial effect, the optimal dose, and the mode of action of inosine pranobex remain to be clarified....
We conclude that treatment with inosine pranobex delays progression to AIDS in patients with HIV infection. The duration of th …
Immunotherapy of genital warts with inosine pranobex and conventional treatment: double blind placebo controlled study.
Davidson-Parker J, Dinsmore W, Khan MH, Hicks DA, Morris CA, Morris DF. Davidson-Parker J, et al. Genitourin Med. 1988 Dec;64(6):383-6. doi: 10.1136/sti.64.6.383. Genitourin Med. 1988. PMID: 2465265 Free PMC article. Clinical Trial.
Although more patients given inosine pranobex improved than those given placebo, the difference in general response between the two groups was not significant. When other variables (numbers of warts and extent of lesions) were considered, however, the patients given …
Although more patients given inosine pranobex improved than those given placebo, the difference in general response between th …
Efficacy of inosine pranobex oral therapy in subclinical human papillomavirus infection of the vulva: a randomized double-blinded placebo controlled study.
Tay SK. Tay SK. Int J STD AIDS. 1996 Jul;7(4):276-80. doi: 10.1258/0956462961917960. Int J STD AIDS. 1996. PMID: 8876359 Clinical Trial.
A randomized double-blind placebo controlled study was carried out to assess the efficacy of inosine pranobex (1 g orally 3 times a day for 6 weeks) in the treatment of symptomatic subclinical human papillomavirus infection of the vulva. In a series of 55 women, 22 …
A randomized double-blind placebo controlled study was carried out to assess the efficacy of inosine pranobex (1 g orally 3 ti …
Randomised, double blind, placebo controlled trial of inosine pranobex in rheumatoid arthritis.
Brzeski M, Madhok R, Hunter JA, Capell HA. Brzeski M, et al. Ann Rheum Dis. 1990 May;49(5):293-5. doi: 10.1136/ard.49.5.293. Ann Rheum Dis. 1990. PMID: 1693065 Free PMC article. Clinical Trial.
In a randomised, placebo controlled, double blind study inosine pranobex was assessed as a possible second line drug in rheumatoid arthritis. Twenty four patients received inosine pranobex (3 g/day) and 26 patients received placebo for up to 24 weeks. …
In a randomised, placebo controlled, double blind study inosine pranobex was assessed as a possible second line drug in rheuma …
Treatment of first-attack genital herpes--acyclovir versus inosine pranobex.
Mindel A, Kinghorn G, Allason-Jones E, Woolley P, Barton I, Faherty A, Jeavons M, Williams P, Patou G. Mindel A, et al. Lancet. 1987 May 23;1(8543):1171-3. doi: 10.1016/s0140-6736(87)92144-1. Lancet. 1987. PMID: 2437417 Clinical Trial.
77 patients with a first attack of genital herpes were entered into a double-blind trial to compare the efficacy of acyclovir with that of inosine pranobex. 24 patients received acyclovir with that of inosine pranobex, and 28 both drugs. Patients treat …
77 patients with a first attack of genital herpes were entered into a double-blind trial to compare the efficacy of acyclovir with that of …
Suppression of frequently recurring genital herpes: acyclovir v inosine pranobex.
Mindel A, Carney O, Sonnex C, Freris M, Patou G, Williams P. Mindel A, et al. Genitourin Med. 1989 Apr;65(2):103-5. doi: 10.1136/sti.65.2.103. Genitourin Med. 1989. PMID: 2473952 Free PMC article. Clinical Trial.
The suppressive action of acyclovir and inosine pranobex was compared in a randomised double blind controlled trial in patients with frequently recurring genital herpes. Fourteen patients received acyclovir and 17 inosine pranobex. Treatment continued …
The suppressive action of acyclovir and inosine pranobex was compared in a randomised double blind controlled trial in patient …
Clinical and immunological assessment in HIV+ subjects receiving inosine-pranobex. A randomised, multicentric study.
De Simone C, Albertini F, Almaviva M, Angarano G, Chiodo F, Costigliola P, Delia S, Ferlini A, Gritti F, Mazzarello G, et al. De Simone C, et al. Med Oncol Tumor Pharmacother. 1989;6(1):63-7. doi: 10.1007/BF02985225. Med Oncol Tumor Pharmacother. 1989. PMID: 2471025 Clinical Trial.
Inosine-pranobex (methisoprinol, isoprinosine; INPX) is the p-acetamidobenzoic salt of N,N-dimethylamino-2-propanol and inosine in a 3:1 molar ratio. ...
Inosine-pranobex (methisoprinol, isoprinosine; INPX) is the p-acetamidobenzoic salt of N,N-dimethylamino-2-propanol and ino
42 results